Unique ID issued by UMIN | UMIN000018140 |
---|---|
Receipt number | R000021000 |
Scientific Title | Effectiveness and safety of bronchial thermoplasty in the treatment with severe persistent bronchial asthma |
Date of disclosure of the study information | 2015/06/30 |
Last modified on | 2023/07/06 20:24:32 |
Effectiveness and safety of bronchial thermoplasty in the treatment with severe persistent bronchial asthma
Effectiveness and safety of bronchial thermoplasty in patients with severe asthma
Effectiveness and safety of bronchial thermoplasty in the treatment with severe persistent bronchial asthma
Effectiveness and safety of bronchial thermoplasty in patients with severe asthma
Japan |
Bronchial asthma
Pneumology | Clinical immunology |
Others
NO
To clarify the effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma in Japanese patients.
Safety,Efficacy
Asthma exacerbation
Asthma control
Pulmonary function
QOL
Bronchial wall thickness, diameter
Adverse events
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1.Uncontrolled severe asthma patients treated with high dose inhaled corticosteroid and long acting beta 2 agonists
2.Eligible for fiberoptic bronchoscopy
1.Have a pacemaker, internal defibrillator, or other implantable electronic device.
2.Have a known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine, and benzodiazepines.
3.Have been previously treated with BT
4.Active respiratory infection
5.Asthma exacerbation or changing dose of systemic corticosteroids for asthma (up or down) in the past 14 days
6.Known coagulopathy. As with other bronchoscopic procedures, patients should stop taking anticoagulants, antiplatelet agents, aspirin, and NSAIDS before the procedure with physician guidance
30
1st name | Motoyasu |
Middle name | |
Last name | Iikura |
National Center for Global Health and Medicine
Respiratory Medicine
162-8655
Toyama 1-21-1, Shinjukuku, Tokyo, Japan
03-3202-7181
iikura-tky@umin.ac.jp
1st name | Motoyasu |
Middle name | |
Last name | Iikura |
National Center for Global Health and Medicine
Respiratory Medicine
162-8655
Toyama 1-21-1, Shinjukuku, Tokyo, Japan
03-3202-7181
iikura-tky@umin.ac.jp
Department of Respiratory Medicine, National Center for Global Health and Medicine
National Center for Global Health and Medicine
Other
Certified Review Board of National Center for Global Health and Medicine
Toyama 1-21-1, Shinjukuku, Tokyo, Japan
03-3202-7181
kenkyu-shinsa@hosp.ncgm.go.jp
NO
2015 | Year | 06 | Month | 30 | Day |
Partially published
https://www.sciencedirect.com/science/article/pii/S1323893017301077?via%3Dihub
30
Asthma-related Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnaire (ACQ)-5 scores were improved at both 1 and 12 months after BT. Mean FEV1 was increased at 1 and 12 months. The mean annual number of severe exacerbations requiring systemic corticosteroids decreased from 5.8 to 2.0 at 12 months after BT. No serious adverse event was observed.
2023 | Year | 07 | Month | 06 | Day |
2017 | Year | 07 | Month | 29 | Day |
Improvement of Asthma-related Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnaire (ACQ)-5 scores, %FEV1 and reduction of severe asthma exacerbation were obsereved at 12 months after BT.
No longer recruiting
2015 | Year | 06 | Month | 15 | Day |
2015 | Year | 06 | Month | 15 | Day |
2015 | Year | 06 | Month | 30 | Day |
2024 | Year | 04 | Month | 30 | Day |
Prospective study
2015 | Year | 06 | Month | 30 | Day |
2023 | Year | 07 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021000